#United States #Kessler Topaz #Radnor #DURAVYU #EyePoint

Investigation into EyePoint, Inc.: A Call to Action for Affected Investors

Kessler Topaz Meltzer & Check, LLP (KTMC) has initiated an investigation into potential violations of securities laws by EyePoint, Inc. (NASDAQ: EYPT), following significant losses experienced by investors. This comes after the company’s disappointing performance in the Phase 3 clinical trial for DURAVYU™ (vorolanib intravitreal insert), which is aimed at treating wet age-related macular degeneration (wet AMD). On August 17, 2026, EyePoint revealed that the clinical trial did not meet critical pre-specified benchmarks, causing its stock price to plunge more than 66%.

Background of the Situation

The stock's drastic fall, following the announcement of poor trial results, has triggered concerns among investors. For many who purchased EyePoint securities, such an unexpected drop not only signifies potential financial loss but also raises questions about the transparency and accuracy of the company's prior disclosures.

The LUGANO clinical trial results showed that DURAVYU failed to achieve its primary endpoint when tested against the on-label aflibercept. The realization that the product did not perform as anticipated has understandably shaken investor confidence in EyePoint's future prospects and strategic direction.

Legal Options for Investors

Investors who acquired securities of EyePoint, Inc. may have specific legal rights under federal securities laws. Kessler Topaz is advising those who suffered losses to come forward and share their stories. It is imperative for affected investors to understand their options, which may include participating in a class action lawsuit aimed at recovery of financial losses.

The law firm emphasizes that there are no costs or obligations to seek legal guidance, making it accessible for investors to explore their options. Many may find it beneficial to consult with experienced securities attorneys who can provide insights specific to their particular circumstances.

About Kessler Topaz Meltzer & Check, LLP

KTMC is recognized as a leading law firm focusing on plaintiff-side securities litigation and investor protection. With a track record of substantial recoveries in major securities fraud cases, KTMC has bolstered its reputation through consistent advocacy on behalf of individual and institutional investors alike. The firm is well-equipped to support those impacted by potential wrongdoing in the financial markets, providing not only legal representation but also valuable resources to help investors navigate these challenging situations.

With offices located in Pennsylvania and California, Kessler Topaz has a rich history of successfully pursuing claims that return significant recoveries to their clients.

To summarize, any investors who purchased EyePoint securities are encouraged to contact Kessler Topaz for a consultation on their potential claims. The firm is actively seeking insights from those who have been adversely affected by the recent events surrounding EyePoint, emphasizing that proactive steps can lead to recovery and justice against the adverse impacts stemming from unmet clinical trial expectations.

Next Steps for Investors

If you or someone you know has incurred losses as a result of investments in EyePoint, please consider reaching out to Kessler Topaz Meltzer & Check for guidance on the next steps to take under these circumstances.

Contact Information

For inquiries or to discuss your legal rights, investors can reach out to:

• - Jonathan Naji, Esq.
• - Address: 280 King of Prussia Road, Radnor, PA 19087
• - Phone: (484) 270-1453
• - Email: [email protected]

Whether you are looking for legal advice or simply seeking more information, taking action sooner rather than later will generally yield better outcomes in the complex world of securities litigation.